Abstract: A device for preparing a gaseous sample obtained from a solid sample. The device includes a laser source arranged to emit a laser beam which is capable of generating calcination and/or combustion of a portion of the solid sample, a collector arranged to collect a gaseous sample of a gas emitted during the calcination and/or combustion of the portion of the solid sample; the laser beam has an irradiance less than 5 MW/cm2 in a given impact zone on a surface of the sample, and including an optical fibre for propagating the laser beam between the laser source and the given impact zone on the surface of the sample.

Abstract: A ligand of Formula (A): or a carboxylate salt thereof; wherein Y1, Y2 and Y3 each independently represents —COOH or a picolinate of Formula (i): wherein each R1 independently represents a chromophore group; L1, L2 and L3 each independently represents a single bond or a linker; and X1, X2 and X3 each independently represents a hydrogen atom, a coupling function or a bio-vectorizing group. Also, a process for manufacturing the ligand and to a process for manufacturing a chelate by complexation by the ligand of a rare-earth cation, preferably a lanthanide cation. Further, a use of the ligand and/or the chelate in biological imaging and/or photoluminescence imaging.

Abstract: The present invention relates to methods for predicting the risk of developing pulmonary colonization/infection by P. aeruginosa. The inventors analyzed the respiratory tract microbiota from 65 patients sputum samples and compared microbiota data. The inventors found that patients that will remain uninfected from P. aeruginosa exhibited 3-fold higher abundance of Porphyromonas compared to the other groups. In particular, the present invention relates to a method for predicting the risk of developing pulmonary colonization/infection by P. aeruginosa in a subject suffering from cystic fibrosis (CF) comprising measuring the abundance of Porphyromonas genus bacteria in a biological sample obtained from said subject.

Abstract: The disclosed antenna includes: a radiating element disposed in a radiating plane transverse to an axis of the antenna; a reflecting plane, which is transverse to the axis, the radiating plane being located at a predetermined height above the reflecting plane; and a substrate, interposed between the radiating plane and the reflecting plane, and having a constant thickness. This antenna is characterized by a local relative electrical permittivity of the substrate that is a function of the radius, i.e. the distance to the axis, and a height, i.e. a distance to the reflecting plane, the local relative electrical permittivity being, at constant height, increasing as a function of the radius, and, at constant radius, increasing as a function of the height at least for a portion of the substrate in the vicinity of the reflecting plane.

Abstract: The present invention provides SOCE inhibitors that are useful as therapeutic agents in a variety of applications. The present invention also relates to pharmaceutical compositions, products and kits comprising such SOCE inhibitors, and methods of using the SOCE inhibitors in the treatment of a variety of diseases.

Abstract: Pseudomonas aeruginosa (PA) leads to chronic respiratory infections especially in patients with cystic fibrosis patients and chronic obstructive pulmonary disease (COPD), characterized by a high morbidity. After screening Lactobacilli coming from CF expectorations, on their capacity to inhibit two Pseudomonas aeruginosa (PA) virulence factors (elastase, pyocyanin), the inventors evaluated the effect of intranasal administration of Lactobacilli on PA murine pneumonia. The primary outcome was the bacterial lung load 24 hours after PA induced pneumonia. To understand the role of Lactobacillus, the chemokines, the pro and anti-inflammatory BAL rates were also measured. The administration of Lactobacilli cocktail 18 h prior the PA lung infection decreases significantly the lung bacterial load at 24 h post-infection. Although the mechanisms need to be deeply explored, an immunomodulation effect may be involved, notably through the recruitment of neutrophils.

Abstract: A computer-implemented method and a system for providing anatomical landmarks of a subject's body part using a set of measures previously acquired by an ultrasound device including at least one fiducial marker and an imaging sensor. Also, a non-transitory computer readable medium including instructions which, when the program is executed by a computer, cause the computer to carry out the method.

Abstract: New glycolipids derivatives of Formula (I) and their use in the treatment of diseases related with a deregulation of the expression and/or activity of SK3 ion channels. Also, pharmaceutical compositions including compounds of Formula (I) for use in the treatment of diseases related with a deregulation of the expression and/or activity of SK3 ion channels.

Abstract: A method for measuring respiratory parameters of a subject using a range imaging sensor, wherein the method includes: receiving from the range imaging sensor at least one raw image of at least one portion of the torso of the subject, wherein each point of the raw image represents the distance between the range imaging sensor and the subject; generating a surface image of at least one portion of a surface of the torso of the subject by surface interpolation of the raw image; estimating a respiratory signal as a function of time calculated as the spatial average, in a given region of interest (ROI) defined on the torso of the subject, of the differences between the depth values of the surface image at a given time and the depth values of a reference surface image; and estimating a lung volume.

Abstract: Activating transcription factor 6 (ATF6) is involved in cystic fibrosis transmembrane conductance regulator (CFTR) repression and understanding this inhibitory mechanism is of great interest to develop a therapeutic approach based on UPR regulation. Using site-1 protease (S1P) inhibitor (e.g. PF-429242) the inventors showed that both membrane localization and function of F508del-CFTR are partially restored. Accordingly, the present invention relates to a method of treating a disease associated with reduced CFTR function in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a S1P inhibitor.

Abstract: A protein hydrolysate obtained from at least one protein source from bluefish having (i) a degree of hydrolysis (DH) of at least 10%, (ii) at least 80% water-soluble protein with a molecular weight of less than 1000 Da, (iii) at least 0.3% phospholipids, and (iv) at least 0.5% DHA and EPA.

Abstract: Pseudomonas aeruginosa (PA) leads to chronic respiratory infections especially in patients with cystic fibrosis patients and chronic obstructive pulmonary disease (COPD), characterized by a high morbidity. After screening Lactobacilli coming from CF expectoration, on their capacity to inhibit two Pseudomonas aeruginosa (PA) virulence factors (elastase, pyocyanin), the inventors evaluated the effect of intranasal administration of Lactobacilli on PA murine pneumonia. The primary outcome was the bacterial lung load 24 hours after PA induced pneumonia. To understand the role of Lactobacillus, the chemokines, the pro and anti-inflammatory BAL rates were also measured. The administration of Lactobacilli cocktail 18 h prior the PA lung infection decreases significantly the lung bacterial load at 24 h post-infection. Although the mechanisms need to be deeply explored, an immunomodulation effect may be involved, notably through the recruitment of neutrophils.

Abstract: The present invention relates to the identification of a novel allele of the RHD gene associated with a weak D phenotype and the kits and methods for detecting this allele.

Abstract: Ligands that are based on the pyclen macrocycle that are reinforced, which are useful for complexing elements such as radioelements and/or elements with magnetic properties.

Abstract: A method for controlling the delivery of a breathing gas to a patient. The method comprises: delivering a flow of breathing gas to a patient, the breathing gas having a breathing gas flowrate and a fraction of inspired oxygen; measuring an oxygen saturation level of the patient; determining a respiratory rate of the patient; automatically adjusting the fraction of inspired oxygen of the breathing gas based on the measured oxygen saturation level of the patient and a breathing gas flowrate set-point; and automatically adjusting the breathing gas flowrate set-point based on the determined respiratory rate of the patient.

Abstract: The present invention relates to novel bis-hydrazone derivatives of formula (I): wherein Ar1 and Ar2 may be identical or different and are each independently selected from the group consisting of groups of formula (II) and (III): Y1 and Z1 are independently CH or NRc+, provided that al least one of Y1 and Z1 is NRc+ and at least one of Y1 and Z1 is CH, and Ra, Rb, Rc, X2? and L as defined in the claims, or a hydrate or a solvate thereof. Compositions and kits comprising same are also described. Said bis-hydrazone derivatives of formula (I), compositions and kits are useful as drugs, in particular for treating or preventing cancers associated with the Epstein-Barr Virus.

Abstract: A macrocycle compound of general formula (X) in which Y1 represents a C(O)OH group or a group of formula (II)

Abstract: A ligand of Formula (A): or a carboxylate salt thereof; wherein Y1, Y2 and Y3 each independently represents —COOH or a picolinate of Formula (i): wherein each R1 independently represents a chromophore group; L1, L2 and L3 each independently represents a single bond or a linker; and X1, X2 and X3 each independently represents a hydrogen atom, a coupling function or a bio-vectorizing group. Also, a process for manufacturing the ligand and to a process for manufacturing a chelate by complexation by the ligand of a rare-earth cation, preferably a lanthanide cation. Further, a use of the ligand and/or the chelate in biological imaging and/or photoluminescence imaging.

Abstract: The present invention relates to an isolated bacterium from the genus Pseudoalteromonas for its use as a probiotic, the use of said strain as a preservative, cyclolipopeptides which may be obtained from this bacterium, a composition comprising at least such a cyclolipopeptide, as well as to their uses.

Abstract: The present invention relates to compounds, ligands, and/or complexes that are useful in medical imaging and/or in therapy, especially in cancer treatment. The present invention also relates to a pharmaceutical composition comprising said compounds, ligands, and/or complexes that are useful for medical imaging, targeting, and/or treatment of cancers. The present invention also relates to a process for preparing these compounds, ligands, and/or complexes.